{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:41:53Z","timestamp":1791942113117,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Roland Ernst Stiftung f\u00fcr Gesundheitswesen","award":["03\/13"],"award-info":[{"award-number":["03\/13"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cca.2019.03.1620","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T12:42:49Z","timestamp":1553085769000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy"],"prefix":"10.1016","volume":"494","author":[{"given":"Mirko","family":"Peitzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Mangelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-9903","authenticated-orcid":false,"given":"Graeme","family":"Eisenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cca.2019.03.1620_bb0005","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.cca.2019.03.1620_bb0010","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.cca.2019.03.1620_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-13-0529","article-title":"Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites","volume":"169","author":"van Duinen","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.cca.2019.03.1620_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.cca.2019.03.1620_bb0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/pbc.25385","article-title":"Pediatric reference intervals for plasma free and Total Metanephrines established with a parametric approach: relevance to the diagnosis of Neuroblastoma","volume":"62","author":"Franscini","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.cca.2019.03.1620_bb0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0004563216654723","article-title":"Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers","volume":"54","author":"Lam","year":"2017","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2019.03.1620_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2017.11.025","article-title":"3-Methoxytyramine: an independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients","volume":"90","author":"Verly","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.cca.2019.03.1620_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mpo.2950200306","article-title":"Methylated catecholamine metabolites for diagnosis of neuroblastoma","volume":"20","author":"Candito","year":"1992","journal-title":"Med. Pediatr. Oncol."},{"issue":"Pt 1","key":"10.1016\/j.cca.2019.03.1620_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000456329403100101","article-title":"Paediatric reference ranges for urinary catecholamines\/metabolites and their relevance in neuroblastoma diagnosis","volume":"31","author":"Fitzgibbon","year":"1994","journal-title":"Ann. Clin. Biochem."},{"issue":"7","key":"10.1016\/j.cca.2019.03.1620_bb0050","first-page":"533","article-title":"Paediatric reference values for urinary catecholamine metabolites evaluated by high performance liquid chromatography and electrochemical detection","volume":"35","author":"Marchese","year":"1997","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"issue":"Pt 4","key":"10.1016\/j.cca.2019.03.1620_bb0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/000456329202900405","article-title":"Reference values for urinary HMMA, HVA, noradrenaline, adrenaline, and dopamine excretion in children using random urine samples and HPLC with electrochemical detection","volume":"29","author":"Fitzgibbon","year":"1992","journal-title":"Ann Clin Biochem"},{"issue":"6","key":"10.1016\/j.cca.2019.03.1620_bb0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clinbiochem.2008.10.022","article-title":"Reference intervals for urinary catecholamines and metabolites from birth to adulthood","volume":"42","author":"Pussard","year":"2009","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2019.03.1620_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/acb.2010.010062","article-title":"Tormey, establishment of a pediatric age-related reference interval for the measurement of urinary total fractionated metanephrines","volume":"48","author":"Griffin","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2019.03.1620_bb0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1258\/acb.2011.011023","article-title":"Age-related medical decision limits for urinary free (unconjugated) metadrenalines, catecholamines and metabolites in random urine specimens from children","volume":"48","author":"Davidson","year":"2011","journal-title":"Ann. Clin. Biochem."},{"issue":"15","key":"10.1016\/j.cca.2019.03.1620_bb0075","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.clinbiochem.2016.05.008","article-title":"Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas","volume":"49","author":"Patin","year":"2016","journal-title":"Clin. Biochem."},{"issue":"11","key":"10.1016\/j.cca.2019.03.1620_bb0080","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of Chromaffin cell Tumors in patients at high and low risk of disease: plasma versus urinary free or Deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.cca.2019.03.1620_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2125.1981.tb01106.x","article-title":"A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine","volume":"11","author":"Brown","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.cca.2019.03.1620_bb0090","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/cs0750515","article-title":"Derivation of urinary dopamine from plasma dopa","volume":"75","author":"Zimlichman","year":"1988","journal-title":"Clin. Sci. (Lond)"},{"issue":"6","key":"10.1016\/j.cca.2019.03.1620_bb0095","doi-asserted-by":"crossref","first-page":"887","DOI":"10.7326\/0003-4819-105-6-887","article-title":"Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma","volume":"105","author":"Goldstein","year":"1986","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.cca.2019.03.1620_bb0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/00365510152567121","article-title":"Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma","volume":"61","author":"Eldrup","year":"2001","journal-title":"Scand. J. Clin. Lab. Investig."},{"issue":"1","key":"10.1016\/j.cca.2019.03.1620_bb0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/08880019609033369","article-title":"3,4-dihydroxyphenylalanine (DOPA) metabolism in screening-detected and non-screening-detected neuroblastoma","volume":"13","author":"Ikeda","year":"1996","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2019.03.1620_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1258\/acb.2012.012112","article-title":"Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultra performance liquid chromatography - tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma","volume":"50","author":"Peitzsch","year":"2013","journal-title":"Ann. Clin. Biochem."},{"issue":"7","key":"10.1016\/j.cca.2019.03.1620_bb0115","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1373\/clinchem.2015.239962","article-title":"Interference from 3-O-methyldopa with ultra-high performance LC-MS\/MS Measurments of plasma Metanephrines: chromatographic Seperation remains important","volume":"61","author":"Peitzsch","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2019.03.1620_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/1467-985X.00091","article-title":"A method for estimating age-specific reference intervals ('normal ranges') based on fractional polynomials and exponential transformation","volume":"161","author":"Royston","year":"1998","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"key":"10.1016\/j.cca.2019.03.1620_bb0125","unstructured":"Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guidelines. Third Edition., Clinical and Laboratory Standards Institute, Wayne, PA2008."},{"issue":"5","key":"10.1016\/j.cca.2019.03.1620_bb0130","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jcem.87.5.8446","article-title":"Utility of plasma free metanephrines for detecting childhood pheochromocytoma","volume":"87","author":"Weise","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Pt 1","key":"10.1016\/j.cca.2019.03.1620_bb0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1258\/acb.2012.012066","article-title":"Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma","volume":"50","author":"Eisenhofer","year":"2013","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2019.03.1620_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cca.2017.05.002","article-title":"Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS\/MS: impact of gender, age, oral contraceptives, body mass index and blood pressure status","volume":"470","author":"Eisenhofer","year":"2017","journal-title":"Clin. Chim. Acta"},{"issue":"7","key":"10.1016\/j.cca.2019.03.1620_bb0145","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/ajmg.a.33407","article-title":"Pheochromocytoma in a 2.75-year-old-girl with a germline von Hippel-Lindau mutation Q164R","volume":"152","author":"Sovinz","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"10.1016\/j.cca.2019.03.1620_bb0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1515\/jpem.2010.102","article-title":"Cushing syndrome in an infant due to cortisol secreting adrenal pheochromocytoma: a rare association","volume":"23","author":"Kumar","year":"2010","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.cca.2019.03.1620_bb0155","doi-asserted-by":"crossref","first-page":"1661.e9","DOI":"10.1016\/j.avsg.2015.06.086","article-title":"A rare case of a massive carotid body tumor in a 3-year-old infant: case presentation and a literature review","volume":"29","author":"Bensaid","year":"2015","journal-title":"Ann. Vasc. Surg."},{"key":"10.1016\/j.cca.2019.03.1620_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cca.2014.01.034","article-title":"Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots","volume":"431","author":"Chen","year":"2014","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.cca.2019.03.1620_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2016.05.011","article-title":"3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency","volume":"118","author":"Chien","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.cca.2019.03.1620_bb0170","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/adc.50.8.665-d","article-title":"Proceedings: significance of 3-methoxytyrosine and its metabolites in urine of patients with sympathetic nervous system tumours","volume":"50","author":"Penchansky","year":"1975","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"10.1016\/j.cca.2019.03.1620_bb0175","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3565(25)31537-5","article-title":"Tubular secretion and metabolism of dopamine, norepinephrine, methoxytyramine and normetanephrine by the rat kidney","volume":"208","author":"Baines","year":"1979","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.cca.2019.03.1620_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF01250336","article-title":"Age-related changes in catecholamine metabolites of human urine from birth to adulthood","volume":"46","author":"Dalmaz","year":"1979","journal-title":"J. Neural Transm."},{"issue":"10","key":"10.1016\/j.cca.2019.03.1620_bb0185","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1096\/fj.02-0736com","article-title":"Tyrosinase: a developmentally specific major determinant of peripheral dopamine","volume":"17","author":"Eisenhofer","year":"2003","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.cca.2019.03.1620_bb0190","first-page":"455","article-title":"Post-natal fate of the abdominal Para-aortic bodies in man","volume":"88","author":"Coupland","year":"1954","journal-title":"J. Anat."},{"issue":"1","key":"10.1016\/j.cca.2019.03.1620_bb0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2826.2012.02367.x","article-title":"Cell loss and autophagy in the extra-adrenal chromaffin organ of Zuckerkandl are regulated by glucocorticoid signalling","volume":"25","author":"Schober","year":"2013","journal-title":"J. Neuroendocrinol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119317255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119317255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:48:09Z","timestamp":1757861289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119317255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"alternative-id":["S0009898119317255"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.03.1620","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.03.1620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}